Perspective Therapeutics (CATX) EBITDA (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of EBITDA data on file, last reported at -$28.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 29.54% year-over-year to -$28.3 million; the trailing twelve-month figure through Mar 2026 stood at -$110.5 million (down 10.84% YoY), and the FY2025 full-year result was -$113.6 million, down 24.95% from the prior year.
• EBITDA improved to -$28.3 million in Q1 2026, from -$38.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.4 million in Q1 2022 to a low of -$45.0 million in Q4 2024.
• A 5-year average of -$16.6 million and a median of -$13.0 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 609.38% in 2023 and advanced 14.9% in 2025, its largest moves.
• Tracing CATX's EBITDA over 5 years: stood at -$5.6 million in 2022, then sank by 107.72% to -$11.7 million in 2023, then sank by 285.27% to -$45.0 million in 2024, then rose by 14.9% to -$38.3 million in 2025, then gained by 26.12% to -$28.3 million in 2026.
• Business Quant data shows CATX's EBITDA at -$28.3 million in Q1 2026, -$38.3 million in Q4 2025, and -$24.1 million in Q3 2025.